Shandong Weigao Group Medical Polymer Company Limited (HKG: 1066)
Hong Kong
· Delayed Price · Currency is HKD
4.360
-0.020 (-0.46%)
Jan 3, 2025, 4:08 PM HKT
Shandong Weigao Group Medical Polymer Company Revenue
Shandong Weigao Group Medical Polymer Company had revenue of 6.64B CNY in the half year ending June 30, 2024, a decrease of -6.26%. This brings the company's revenue in the last twelve months to 12.97B, down -4.42% year-over-year. In the year 2023, Shandong Weigao Group Medical Polymer Company had annual revenue of 13.23B, down -3.77%.
Revenue (ttm)
12.97B CNY
Revenue Growth
-4.42%
P/S Ratio
1.41
Revenue / Employee
1.04M CNY
Employees
12,519
Market Cap
19.93B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 13.23B | -518.02M | -3.77% |
Dec 31, 2022 | 13.75B | 538.53M | 4.08% |
Dec 31, 2021 | 13.21B | 1.59B | 13.65% |
Dec 31, 2020 | 11.62B | 1.24B | 11.93% |
Dec 31, 2019 | 10.38B | 1.58B | 17.88% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 26.04B |
Hansoh Pharmaceutical Group Company | 13.00B |
JD Health International | 58.84B |
WuXi Biologics | 18.39B |
Sinopharm Group | 634.32B |
Innovent Biologics | 8.01B |
Sino Biopharmaceutical | 29.86B |
CSPC Pharmaceutical Group | 33.53B |